Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
5
×
life sciences
national blog main
biotech
boston
national top stories
san francisco blog main
startups
clinical trials
deals
gene therapy
new york blog main
san diego blog main
san francisco top stories
third rock ventures
vc
20/20 healthcare partners
acetylon pharmaceuticals
ally bridge group
ambys medicines
amgen ventures
amyotrophic lateral sclerosis
anthony despasqua
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
big data analytics
blackrock
bluebird bio
casdin capital
cell therapy
christian angermayer
constellation pharmaceuticals
crispr
david walt
diabetic nephropathy
diagnostics
dolby family ventures
What
diseases
5
×
medicines
new
bio
biotech
develop
drug
genetic
ipo
raised
ago
aiming
ambys
analysis
associated
big
biotechs
bring
companies
company
considering
control
create
crispr
data
deadly
deal
debuted
device
diagnostic
dialysis
disease
drugs
dyne
early
editing
employing
enclear
expected
experimental
Language
unset
Current search:
" boston top stories "
×
diseases
×
@xconomy.com
4 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
6 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?